Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
D.KaczmarekA.KryskoO.AgostinisP.VandenabeeleP
Neuroendocrinology 97 , 300308 (2013)
Several factors contribute to these elevated costs: Patent protection Most GLP-1 medications are still under patent, preventing generic competition Manufacturing complexity These are biologic medications that require specialized production processes Research and development costs Pharmaceutical companies invest heavily in clinical trials and regulatory approval Market positioning These medications are often priced as premium treatments Without insurance coverage, patients face the full retail price, which can make these medications financially inaccessible for many people who need them
Ussher JR, Drucker DJ: Cardiovascular actions of incretin-based therapies
US$ 20.59
US$ 25.58
US$ 26.05
